20(R)-Ginsenoside Rh2

Synonyms: 20(R)-人参皂苷Rh2
20(R)-Ginsenoside Rh2 是一种口服有效的原人参二醇型皂苷,具有多种生物活性:它通过诱导细胞周期阻滞和促进凋亡 (apoptosis) 对非小细胞肺癌和肝癌发挥显著抑制作用,通过抑制病毒 DNA 复制发挥抗 γ-疱疹病毒作用,通过降低一氧化氮 (NO)、前列腺素 E2 (PGE2) 和活性氧 (ROS) 水平抑制炎症介质,通过减少 ROS 和抑制 MMP-9/2 延缓皮肤光老化,通过激活 Akt1/PKB 信号通路加速肌肉损伤后的恢复,并通过抑制破骨细胞形成发挥抗骨质疏松作用。
产品编号: MS-Y15594 纯度: 99.84% CAS No.: 112246-15-8 分子式: C36H62O8 分子量: 622.87
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

20(R)-Ginsenoside Rh2 是一种口服有效的原人参二醇型皂苷,具有多种生物活性:它通过诱导细胞周期阻滞和促进凋亡 (apoptosis) 对非小细胞肺癌和肝癌发挥显著抑制作用,通过抑制病毒 DNA 复制发挥抗 γ-疱疹病毒作用,通过降低一氧化氮 (NO)、前列腺素 E2 (PGE2) 和活性氧 (ROS) 水平抑制炎症介质,通过减少 ROS 和抑制 MMP-9/2 延缓皮肤光老化,通过激活 Akt1/PKB 信号通路加速肌肉损伤后的恢复,并通过抑制破骨细胞形成发挥抗骨质疏松作用。

生物实验数据

生物活性 20(R)-Ginsenoside Rh2 is an orally effective protopanaxadiol-type saponin with multiple bioactivities: it exerts significant inhibitory effects on non-small cell lung cancer and liver cancer by inducing cell cycle arrest and promoting apoptosis, exhibits anti-γ-herpesvirus activity by inhibiting viral DNA replication, suppresses inflammatory mediators by reducing nitric oxide (NO), prostaglandin E2 (PGE2), and reactive oxygen species (ROS) levels, delays skin photoaging by decreasing ROS and inhibiting MMP-9/2, accelerates recovery after muscle injury by activating the Akt1/PKB signaling pathway, and exerts anti-osteoporotic effects by inhibiting osteoclast formation.
IC50 & Target

MMP9

 

MMP2

 

Akt1

 

体外研究
(In Vitro)

20(R)-Ginsenoside Rh2 (0-50 μM, 24 h) 能够抑制 NO、PGE2、ROS 和 MMP-9 (基质金属蛋白酶-9) 的产生,但不能调节由 LPS (MS-X54539) 在 RAW264.7 巨噬细胞中诱导的 MMP-2 (基质金属蛋白酶-2) 的明胶酶活性。
20(R)-Ginsenoside Rh2 (0-25 μM, 24 h) 降低 ROS 水平 (但不能调节 NO),抑制未受刺激的 HaCat 细胞中 MMP-9 和 MMP-2 的明胶酶活性,且对 HaCat 细胞无细胞毒性。
20(R)-Ginsenoside Rh2 (0-200 μg/mL, 24 h-28 d) 抑制 95D 和 NCI-H460 细胞的增殖和集落形成,并诱导这两种细胞凋亡。
20(R)-Ginsenoside Rh2 (50-100 μg/mL, 48 h) 介导 95D 细胞的 G1/S 期细胞周期阻滞和 NCI-H460 细胞的 G2 期细胞周期阻滞。
20(R)-Ginsenoside Rh2 (0-100 μM, 72 h) 通过抑制 MHV-68 进入 NIH-3T3 细胞后的复制,显著抑制小鼠 γ 疱疹病毒68 (MHV-68) 的增殖 (IC50 = 2.77 μM),且抑制人 γ 疱疹病毒 (KSHV) 阳性细胞系 BC3 的裂解复制。
20(R)-Ginsenoside Rh2 (5-10 μg/mL, 72 h) 通过激活 Akt/PKB 信号通路并抑制 p27Kip1 和 p57KIP2 的表达,增加 C2C12 小鼠成肌细胞的增殖并抑制原代大鼠心肌细胞的增殖。
20(R)-Ginsenoside Rh2 对破骨细胞形成有抑制作用 (IC50 = 12 μM),对破骨细胞增殖无抑制作用。

Western Blot Analysis

Cell Line: HaCat cells
Concentration: 0, 0.2, 1, 5 and 25 μM
Incubation Time: 24 h
Result: Observed the reduction of MMP-9 and MMP-2 gelatinolytic activity.
Inhibited TNF-a-induced MMP-9 gelatinolytic activity.

Cell Proliferation Assay

Cell Line: 95D and NCI-H460 cells
Concentration: 0, 50, 100, 200 µg/mL
Incubation Time: 24, 48 and 72 h
Result: Exhibited the IC50s of 1006.15, 491.46 and 596.81 µg/mL at 24, 48 and 72 h against 95D cells.
Exhibited the IC50s of 386,77, 783,49 and 368,32 µg/mL at 24, 48 and 72 h against NCI-H460 cells.

Cell Cycle Analysis

Cell Line: 95D and NCI-H460 cells
Concentration: 50 and 100 µg/mL
Incubation Time: 48 h
Result: Increased the accumulation rate of 95D cells in S phase from 34.70% to 43.05% and that of NCI‑H460 cells in S phase is 3.64% to 22.94% at 100 µg/mL.

Apoptosis Analysis

Cell Line: 95D and NCI-H460 cells
Concentration: 50 and 100 µg/mL
Incubation Time: 48 h
Result: Had the maximum total apoptosis rate of 21.67% in 95D cells and NCI‑H460 cells total apoptosis rate was 27.30%.
The number of nuclear fragmentation (apoptotic bodies) has significantly increased.

RT-PCR

Cell Line: NIH-3T3 cells infected MHV-68
Concentration: 100 µM
Incubation Time: 72 h
Result: Reduced the mRNA expression of the viral lysate gene RTA.
Reduced the expression of the RTA (key gene during the lytic phase) and ORF56 (gene related to DNA synthesis).

Western Blot Analysis

Cell Line: NIH-3T3 cells infected MHV-68
Concentration: 100 µM
Incubation Time: 72 h
Result: Significantly decreased the expression of the late viral protein ORF45 (capsid protein) and M9.

Immunofluorescence

Cell Line: C2C12 murine myoblasts
Concentration: 5 and 10 µg/mL
Incubation Time: 72 h
Result: Selectively enhanced myoblast proliferation (BrdU of human primary cells increased by 35%).
Inhibited the proliferation of cardiac fibroblasts (CdF).

RT-PCR

Cell Line: C2C12 myoblast cells and primary rat cardiomyocytes
Concentration: 5 µg/mL
Incubation Time: 72 h
Result: Significantly downregulated p27Kip1 and p57Kip2 mRNA in C2C12 myoblast cells.
Downregulated p27Kip1 and showed no change on p57Kip2 in primary rat cardiomyocytes.

Western Blot Analysis

Cell Line: C2C12 myoblast cells and primary rat cardiomyocytes
Concentration: 5 and 10 µg/mL
Incubation Time: 72 h
Result: Significantly increased Akt phosphorylation in C2C12 myoblast cells.
Consistented with the mRNA results.
体内研究
(In Vivo)

20(R)-Ginsenoside Rh2 (2-6 mg/kg, p.o., 每日一次共 10 天) 通过下调 Bcl-2 诱导肿瘤细胞凋亡,在小鼠肝癌模型中发挥了显著的抗肿瘤效果。
20(R)-Ginsenoside Rh2 (2 mg/kg, i.p., 每日一次共 7 天) 可促进心肌梗死大鼠模型中心肌细胞的增殖并改善心脏功能。
20(R)-Ginsenoside Rh2 (2 mg/kg, i.p., 每日一次共 7-14 天) 可加速骨骼肌退化小鼠模型中骨骼肌的再生并减少纤维化。
20(R)-Ginsenoside Rh2 (5 μg/mL) 可增强斑马鱼心肌细胞的增殖。

Animal Model: Myocardial infarction model established in adult male 8-week-old Sprague Dawley rats (weight range 230-250 g)
Dosage: 2 mg/kg
Administration: Intraperitoneal injection (i.p.), once daily, for 7 days
Result: Increased ejection fraction (EF) by 28%, left ventricular wall thickness increased, and scar area decreased.
Animal Model: Hepatoma model established in female H22 hepatoma-bearing mice (18-22g)
Dosage: 2, 3, 4, 6mg/kg
Administration: Oral administration (p.o.), once daily for 10 days
Result: Significantly inhibited tumor growth, and the weight of the mice remained stable.
The number of nuclear divisions decreased, the area of necrosis increased, and apoptotic-like cells (with nuclear shrinkage and fragmentation) were significantly present.
Significantly downregulated the expression of Bcl-2, Bax/Bak/Bcl-xL, but no significant change was observed.
Animal Model: Skeletal muscle degeneration model established in 8-week-old male C57BL/6 mice (weight range 23-25 g)
Dosage: 2 mg/kg
Administration: Intraperitoneal injection (i.p.), once daily, for 7 and 14 days
Result: Observed a large number of central nuclear myofibers (indicative of new formation) with their diameters significantly increased compared to the control group during 7 days treatment.
The number of inflammatory cells decreased by 50% during 7 days treatment.
Arranged more closely in the muscle fibers, reduced the scar area, and the swimming time remained stable during 14 days treatment.
性状 固体
颜色 White to off-white

化学信息

分子量 622.87
分子式 C36H62O8
CAS No. 112246-15-8
别名 20(R)-人参皂苷Rh2

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (160.55 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.6055 mL8.0274 mL16.0547 mL40.1368 mL
5 mM0.3211 mL1.6055 mL3.2109 mL8.0274 mL
10 mM0.1605 mL0.8027 mL1.6055 mL4.0137 mL
15 mM0.1070 mL0.5352 mL1.0703 mL2.6758 mL
20 mM0.0803 mL0.4014 mL0.8027 mL2.0068 mL
25 mM0.0642 mL0.3211 mL0.6422 mL1.6055 mL
30 mM0.0535 mL0.2676 mL0.5352 mL1.3379 mL
40 mM0.0401 mL0.2007 mL0.4014 mL1.0034 mL
50 mM0.0321 mL0.1605 mL0.3211 mL0.8027 mL
60 mM0.0268 mL0.1338 mL0.2676 mL0.6689 mL
80 mM0.0201 mL0.1003 mL0.2007 mL0.5017 mL
100 mM0.0161 mL0.0803 mL0.1605 mL0.4014 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

20(R)-人参皂苷Rh2 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础